New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its ...

One patient with TNBC describes the challenges she faced trying to de-escalate a grueling treatment regimen despite warnings ...

PORTOS can determine which patients with localized prostate cancer will benefit from dose-escalation of radiotherapy, data suggest.

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

Agenus Inc. , a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...